| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.025 | 0.7 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.028 | 0.7 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.021 | 0.7 |